ZYBERNO
Stock Report
Updated Jun 7, 2026

Kezar Life Sciences, Inc. (KZR)

Healthcare • NASDAQ

$7.29

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Kezar Life Sciences, Inc. (KZR) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-58.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.04x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-2,134.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Kezar Life Sciences, Inc. (KZR) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, KZR generated -$42.03M in Owner Earnings. Reinvestment rate: 2.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:7.29
Market Cap:$53.54M

Valuation Multiples (2)

P/B Ratio:0.82x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$9.98M
B. Profitability Assessment

Return Metrics (5)

ROA:-51.5%
Reinvestment Rate:2.4%
Fundamental Growth Rate (g):-51.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$84.64
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:70.9%
Latest Earnings Filed:2026-05-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:24.46x
Quick Ratio:24.46x
Cash Ratio:23.98x

Leverage Analysis (3)

Debt To Equity Ttm:0.04x
Debt-to-Equity Ratio:0.04x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-56.94x
Times Interest Earned:-56.94

Capital Structure (4)

Working Capital:64,801,000.00
Cash And Cash Equivalents:66,229,000.00
Long Term Debt:$1.35M
Net Debt:-$63.52M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$48.84M

Bottom Line Performance (3)

-$45.23M
Income Before Tax:-$56.03M
Ebitda Ttm:-48,150,000.00

Operating Expenses (5)

Operating Expenses:48,843,000.00
R And D Expense:23,121,000.00
Sga Expense:18,273,000.00
Income Tax Expense:$0.00
Interest Expense:1,038,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$68.00M
Current Assets:$67.56M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,762,000.00
Current Liabilities:2,762,000.00
Long Term Debt:$1.35M
Short Term Debt:$1.35M

Equity & Capital (3)

Equity:$65.24M
Retained Earnings:-$496.29M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,135,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:653,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$42.03M-$42.03M

Investment Activities (2)

Investing Cash Flow:$1.53M
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$267.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:693,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-6.17
-$6.17
Earnings Per Share Ttm:-$6.16

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$7.05

Book Value & Capital (2)

Book Value Per Share:$8.88
Cash Per Share:9.02

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$42.03M

Damodaran Growth Analysis (2)

Reinvestment Rate:2.4%
Fundamental Growth Rate (g):-51.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-25.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:KZR
Company Name:Kezar Life Sciences, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:7.34M
Shares Outstanding Basic:7.34M
Shares Outstanding Diluted:7.34M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-07 14:41:11 UTC
Data Timestamp:2026-06-06T21:01:22.014431
Scroll to Top